Under the terms of the agreement, MC2 will receive upfront and regulatory milestone payments of $16 million, and an additional $36 million if certain sales milestones are achieved. The company is also eligible to receive tiered double-digit royalties.
In addition, Huadong will have oversight of a joint steering committee comprised of individuals from both companies.
Wynzora Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults.
Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product.
The treatment was approved in the US by the FDA on July 20th, 2020, and in the first country in Europe on July 9th, 2021.
Jesper Lange, CEO of MC2, said: “As a leading pharmaceutical company in Asia with a clear ambition and strategy to grow its franchise in treatment of immune-mediated skin diseases, Huadong is an excellent partner to leverage Wynzora in Greater China.”
“This deal substantiates our strategy to make Wynzora available to as many people as possible globally, as we continue to develop and expand our pipeline of innovative first-in-class treatments for immune-mediated inflammatory conditions.”
Liang Lu, CEO and chairman of Huadong Medicine, added: “MC2’s commitment to develop novel treatment paradigms within immune-mediated inflammatory skin diseases synergizes with Huadong’s presence and ambition to be a leader in this area.”
“Wynzora, MC2’s first commercialized drug, is a proven effective treatment for plaque psoriasis launched in the US and EU. Leveraging Huadong’s clinical, regulatory and commercial capabilities, we will work closely with MC2 to accelerate the clinical development of Wynzora in Greater China, to benefit patients suffering from psoriasis, as soon as possible.”